These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 15319237)

  • 1. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials.
    Folprecht G; Cunningham D; Ross P; Glimelius B; Di Costanzo F; Wils J; Scheithauer W; Rougier P; Aranda E; Hecker H; Köhne CH
    Ann Oncol; 2004 Sep; 15(9):1330-8. PubMed ID: 15319237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
    Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL
    Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer.
    Garcia-Giralt E; Beuzeboc P; Deffontaines D; Diéras V; Dorval T; Jouve M; Palangie T; Scholl S; Pouillart P
    J Infus Chemother; 1996; 6(3):149-51. PubMed ID: 9229328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: a north central cancer treatment group study.
    D'Andre S; Sargent DJ; Cha SS; Buroker TR; Kugler JW; Goldberg RM; O'Connell MJ; Poon MA
    Clin Colorectal Cancer; 2005 Jan; 4(5):325-31. PubMed ID: 15663836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palliative 5-fluorouracil-based chemotherapy for advanced colorectal cancer in the elderly: results of a 10-year experience.
    Magné N; François E; Broisin L; Guardiola E; Ramaïoli A; Ferrero JM; Namer M
    Am J Clin Oncol; 2002 Apr; 25(2):126-30. PubMed ID: 11943888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.
    Van Cutsem E; Blijham GH
    Semin Oncol; 1999 Feb; 26(1 Suppl 5):13-20. PubMed ID: 10213010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The incidence and cost of hospitalization for 5-FU toxicity among Medicare beneficiaries with metastatic colorectal cancer.
    Delea TE; Vera-Llonch M; Edelsberg JS; McGarry L; Anton S; Ulcickas-Yood M; Oster G
    Value Health; 2002; 5(1):35-43. PubMed ID: 11873382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure.
    Schmitt C; Blijham G; Jolain B; Rougier P; Van Cutsem E
    Anticancer Drugs; 1999 Jul; 10(6):617-23. PubMed ID: 10885910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
    Köhne CH; Wils J; Lorenz M; Schöffski P; Voigtmann R; Bokemeyer C; Lutz M; Kleeberg C; Ridwelski K; Souchon R; El-Serafi M; Weiss U; Burkhard O; Rückle H; Lichnitser M; Langenbuch T; Scheithauer W; Baron B; Couvreur ML; Schmoll HJ;
    J Clin Oncol; 2003 Oct; 21(20):3721-8. PubMed ID: 12963704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil.
    Anderson N; Lokich J; Moore C; Bern M; Coco F
    Cancer Invest; 1999; 17(8):586-93. PubMed ID: 10592766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose infusional 5-fluorouracil combination therapy of metastatic gastric and colorectal cancer.
    Loeffler TM; Hausamen TU
    J Infus Chemother; 1996; 6(3):137-40. PubMed ID: 9229325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy.
    Chiara S; Nobile MT; Vincenti M; Lionetto R; Gozza A; Barzacchi MC; Sanguineti O; Repetto L; Rosso R
    Cancer Chemother Pharmacol; 1998; 42(4):336-40. PubMed ID: 9744780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimens.
    Massacesi C; Pistilli B; Valeri M; Lippe P; Rocchi MB; Cellerino R; Piga A
    Am J Clin Oncol; 2002 Apr; 25(2):140-8. PubMed ID: 11943891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival.
    Zaniboni A
    J Clin Oncol; 1997 Jun; 15(6):2432-41. PubMed ID: 9196159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer.
    Chester JD; Dent JT; Wilson G; Ride E; Seymour MT
    Ann Oncol; 2000 Feb; 11(2):235-7. PubMed ID: 10761764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic overview of chemotherapy effects in colorectal cancer.
    Ragnhammar P; Hafström L; Nygren P; Glimelius B;
    Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study.
    Scheithauer W; Kornek G; Marczell A; Salem G; Karner J; Kovats E; Burger D; Greiner R; Pidlich J; Schneeweiss B; Raderer M; Rosen H; Depisch D
    J Clin Oncol; 1997 Mar; 15(3):908-14. PubMed ID: 9060527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-Fluorouracil versus 5-fluorouracil plus alpha-interferon as treatment of metastatic colorectal carcinoma. A randomized study.
    Dufour P; Husseini F; Dreyfus B; Cure H; Martin C; Prevost G; Olivier JP; Dumas F; Duclos B; Olivares R; Leszler A; Bergerat JP; Audhuy B; Thill L; Oberling F
    Ann Oncol; 1996 Aug; 7(6):575-9. PubMed ID: 8879370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers.
    Sobrero A; Zaniboni A; Frassineti GL; Aschele C; Guglielmi A; Giuliani R; Ravaioli A; Lanfranco C; Caroti C; Arnoldi E; Barni S; Gallo L; Pessi MA; Turci D; Cortesi E; Grossi F; Frontini L; Piazza E; Bruzzi P; Labianca R
    Ann Oncol; 2000 Nov; 11(11):1413-20. PubMed ID: 11142481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
    Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Piñol V; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Payá A; Alenda C;
    Gut; 2006 Jun; 55(6):848-55. PubMed ID: 16299036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.